Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regional lymphatic chemotherapy with activated carbon nanoparticle–epirubicin in esophageal cancer
ChiCTR-IIR-16008115Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of epirubicin and paclitaxel in esophageal cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Drug concentration. Started Mar 2016; status: recruiting.
02
Drugs
epirubicinpaclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR-IIR-16008115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008115.